Cogent Biosciences (COGT) Retained Earnings (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Retained Earnings of -$1.3 billion for Q1 2026, down 38.04% year-over-year from -$2.1 billion in Q1 2025, and down 362297.18% quarter-over-quarter from $355000.0 in Q4 2025.
Cogent Biosciences (COGT) Retained Earnings (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Retained Earnings for 10 consecutive years, with -$1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 38.04% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 38.04% YoY), while the FY2025 annual figure was $355000.0, down 20.58% from the prior year.
- Retained Earnings declined to -$1.3 billion in Q1 2026 per COGT's latest filing, from $355000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $447000.0 in Q4 2024 and bottomed at -$1.3 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$432.9 million across 5 years, with a median of -$336.5 million in 2022.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 100.06% — and 2024, when it slumped 4137425.0%.
- Cogent Biosciences' Retained Earnings stood at -$411.2 million in 2022, then jumped by 100.06% to $246000.0 in 2023, then soared by 81.71% to $447000.0 in 2024, then dropped by 20.58% to $355000.0 in 2025, then sank by 362297.18% to -$1.3 billion in 2026.
- Business Quant data shows COGT's Retained Earnings at -$1.3 billion in Q1 2026, $355000.0 in Q4 2025, and -$1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | -1.38 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.38 Bn |
| Mar 31, 2026 | -1.29 Bn |
| Dec 31, 2025 | 355,000.00 |
| Sep 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | -1.00 Bn |
| Mar 31, 2025 | -931.47 Mn |
| Dec 31, 2024 | 447,000.00 |
| Sep 30, 2024 | -791.56 Mn |
| Jun 30, 2024 | -192,000.00 |
| Mar 31, 2024 | -661.97 Mn |
| Dec 31, 2023 | 246,000.00 |
| Sep 30, 2023 | -549.26 Mn |
| Jun 30, 2023 | -97,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | -411.21 Mn |
| Sep 30, 2022 | -163,000.00 |
| Jun 30, 2022 | -336.50 Mn |
| Mar 31, 2022 | -301.61 Mn |
| Dec 31, 2021 | -270.97 Mn |
| Sep 30, 2021 | -246.10 Mn |